The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis
Factor Xa inhibitors are safe and effective alternatives to warfarin, but several studies indicate that rivaroxaban may cause a different risk profile for bleeding. For instance, while the risk of major bleeding in general may be lower with rivaroxaban than for warfarin, the risk of gastrointestinal...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | Platelets |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09537104.2018.1557618 |
| _version_ | 1797684178022563840 |
|---|---|
| author | Nina Haagenrud Schultz Pål Andre Holme Stine Bjørnsen Carola Elisabeth Henriksson Per Morten Sandset Eva-Marie Jacobsen |
| author_facet | Nina Haagenrud Schultz Pål Andre Holme Stine Bjørnsen Carola Elisabeth Henriksson Per Morten Sandset Eva-Marie Jacobsen |
| author_sort | Nina Haagenrud Schultz |
| collection | DOAJ |
| description | Factor Xa inhibitors are safe and effective alternatives to warfarin, but several studies indicate that rivaroxaban may cause a different risk profile for bleeding. For instance, while the risk of major bleeding in general may be lower with rivaroxaban than for warfarin, the risk of gastrointestinal bleeding or abnormal uterine bleeding may be higher. The underlying mechanisms for these differences are not known, and the effect of rivaroxaban on primary hemostasis is poorly understood. The aim of this study was to investigate the effect of rivaroxaban on platelet function, P-selectin and von Willebrand factor (VWF) antigen and activity. Patients with venous thrombosis assigned to 3 months of treatment due to temporary risk factors were included. Blood was collected both during (on-treatment) and 4–6 weeks after end of treatment (without treatment). The platelet reactivity was assessed by light transmission aggregometry. P-selectin was measured by an enzyme-linked immunosorbent assay and vWF antigen and activity by latex immunoagglutination assays. Platelet reactivity during on-treatment (trough- and peak concentration) was similar to values without treatment. There was a trend toward a reduction of P-selectin during rivaroxaban treatment (peak concentration) compared to value without treatment (p = 0.06). There were no differences in vWF antigen and activity between the different time-points. We found no difference in platelet reactivity or vWF antigen/activity during rivaroxaban treatment compared with values without treatment. Apart from possibly causing a reduction of P-selectin, rivaroxaban seems not to influence primary hemostasis. |
| first_indexed | 2024-03-12T00:26:46Z |
| format | Article |
| id | doaj.art-06d2a660183045189d5073ccaf09412f |
| institution | Directory Open Access Journal |
| issn | 0953-7104 1369-1635 |
| language | English |
| last_indexed | 2024-03-12T00:26:46Z |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Platelets |
| spelling | doaj.art-06d2a660183045189d5073ccaf09412f2023-09-15T10:32:01ZengTaylor & Francis GroupPlatelets0953-71041369-16352020-01-01311434710.1080/09537104.2018.15576181557618The impact of rivaroxaban on primary hemostasis in patients with venous thrombosisNina Haagenrud Schultz0Pål Andre Holme1Stine Bjørnsen2Carola Elisabeth Henriksson3Per Morten Sandset4Eva-Marie Jacobsen5Oslo University HospitalOslo University HospitalOslo University HospitalUniversity of OsloOslo University HospitalOslo University HospitalFactor Xa inhibitors are safe and effective alternatives to warfarin, but several studies indicate that rivaroxaban may cause a different risk profile for bleeding. For instance, while the risk of major bleeding in general may be lower with rivaroxaban than for warfarin, the risk of gastrointestinal bleeding or abnormal uterine bleeding may be higher. The underlying mechanisms for these differences are not known, and the effect of rivaroxaban on primary hemostasis is poorly understood. The aim of this study was to investigate the effect of rivaroxaban on platelet function, P-selectin and von Willebrand factor (VWF) antigen and activity. Patients with venous thrombosis assigned to 3 months of treatment due to temporary risk factors were included. Blood was collected both during (on-treatment) and 4–6 weeks after end of treatment (without treatment). The platelet reactivity was assessed by light transmission aggregometry. P-selectin was measured by an enzyme-linked immunosorbent assay and vWF antigen and activity by latex immunoagglutination assays. Platelet reactivity during on-treatment (trough- and peak concentration) was similar to values without treatment. There was a trend toward a reduction of P-selectin during rivaroxaban treatment (peak concentration) compared to value without treatment (p = 0.06). There were no differences in vWF antigen and activity between the different time-points. We found no difference in platelet reactivity or vWF antigen/activity during rivaroxaban treatment compared with values without treatment. Apart from possibly causing a reduction of P-selectin, rivaroxaban seems not to influence primary hemostasis.http://dx.doi.org/10.1080/09537104.2018.1557618platelet aggregationp-selectinrivaroxabanvon willebrand factor |
| spellingShingle | Nina Haagenrud Schultz Pål Andre Holme Stine Bjørnsen Carola Elisabeth Henriksson Per Morten Sandset Eva-Marie Jacobsen The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis Platelets platelet aggregation p-selectin rivaroxaban von willebrand factor |
| title | The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis |
| title_full | The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis |
| title_fullStr | The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis |
| title_full_unstemmed | The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis |
| title_short | The impact of rivaroxaban on primary hemostasis in patients with venous thrombosis |
| title_sort | impact of rivaroxaban on primary hemostasis in patients with venous thrombosis |
| topic | platelet aggregation p-selectin rivaroxaban von willebrand factor |
| url | http://dx.doi.org/10.1080/09537104.2018.1557618 |
| work_keys_str_mv | AT ninahaagenrudschultz theimpactofrivaroxabanonprimaryhemostasisinpatientswithvenousthrombosis AT palandreholme theimpactofrivaroxabanonprimaryhemostasisinpatientswithvenousthrombosis AT stinebjørnsen theimpactofrivaroxabanonprimaryhemostasisinpatientswithvenousthrombosis AT carolaelisabethhenriksson theimpactofrivaroxabanonprimaryhemostasisinpatientswithvenousthrombosis AT permortensandset theimpactofrivaroxabanonprimaryhemostasisinpatientswithvenousthrombosis AT evamariejacobsen theimpactofrivaroxabanonprimaryhemostasisinpatientswithvenousthrombosis AT ninahaagenrudschultz impactofrivaroxabanonprimaryhemostasisinpatientswithvenousthrombosis AT palandreholme impactofrivaroxabanonprimaryhemostasisinpatientswithvenousthrombosis AT stinebjørnsen impactofrivaroxabanonprimaryhemostasisinpatientswithvenousthrombosis AT carolaelisabethhenriksson impactofrivaroxabanonprimaryhemostasisinpatientswithvenousthrombosis AT permortensandset impactofrivaroxabanonprimaryhemostasisinpatientswithvenousthrombosis AT evamariejacobsen impactofrivaroxabanonprimaryhemostasisinpatientswithvenousthrombosis |